NASDAQ : CMMB
Chemomab Therapeutics Ltd. — Financial statements
Healthcare · Biotechnology · Israel
Last price 1.09 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 7.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 3.79M | 3.73M | 3.41M | 7.08M | 11.56M | 6.03M |
| Research & Development | 4.12M | 5.83M | 11.33M | 18.38M | 16.98M | 6.33M |
| Operating Expenses | 7.91M | 9.57M | 14.74M | 25.46M | 28.53M | 12.37M |
| Operating Income | -7.91M | -9.57M | -14.74M | -25.46M | -28.53M | -12.37M |
| Interest Expense | -111.00K | |||||
| Interest & Investment Income | 231.00K | 447.00K | 785.00K | 1.24M | 353.00K | |
| Currency Exchange Gain (Loss) | 125.00K | 125.00K | 9.00K | |||
| Pretax Income | -7.55M | -8.99M | -13.95M | -24.22M | -28.18M | -12.48M |
| Income Tax Expense | -534.00K | |||||
| Net Income | -7.55M | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M |
| Net Income to Common | -7.55M | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M |
| Shares Outstanding (Basic) | 7.50M | 6.38M | 4.49M | 2.94M | 2.84M | 2.59M |
| Shares Outstanding (Diluted) | 7.50M | 6.38M | 4.49M | 2.94M | 2.84M | 2.59M |
| EPS (Basic) | -1.01 | -1.41 | -3.11 | -8.25 | -9.72 | -4.81 |
| EPS (Diluted) | -1.01 | -1.41 | -3.11 | -8.25 | -9.72 | -4.81 |
| Free Cash Flow | -8.74M | -11.13M | -15.39M | -23.61M | -20.44M | -12.61M |
| Free Cash Flow Per Share | -1.17 | -1.75 | -3.43 | -8.04 | -7.18 | -4.86 |
| EBITDA | -7.85M | -9.50M | -14.69M | -25.39M | -28.48M | -12.33M |
| D&A For EBITDA | 58.00K | 70.00K | 53.00K | 67.00K | 58.00K | 34.00K |
| EBIT | -7.91M | -9.57M | -14.74M | -25.46M | -28.53M | -12.37M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.00M | 7.56M | 6.07M | 9.29M | 13.52M | 15.19M |
| Short-Term Investments | 688.00K | 2.80M | 8.20M | 10.49M | 26.37M | 45.98M |
| Cash & Short-Term Investments | 6.69M | 10.37M | 14.27M | 19.78M | 39.89M | 61.16M |
| Other Receivables | 3.27M | 195.00K | 263.00K | 289.00K | 459.00K | 179.00K |
| Receivables | 3.27M | 195.00K | 263.00K | 289.00K | 459.00K | 179.00K |
| Prepaid Expenses | 2.86M | 1.44M | 748.00K | 1.31M | 1.35M | |
| Restricted Cash | 76.00K | 76.00K | 77.00K | |||
| Total Current Assets | 9.96M | 13.43M | 16.04M | 20.90M | 41.74M | 62.69M |
| Property, Plant & Equipment | 158.00K | 176.00K | 539.00K | 695.00K | 594.00K | 702.00K |
| Other Long-Term Assets | 123.00K | 211.00K | 385.00K | 559.00K | 733.00K | 963.00K |
| Total Assets | 10.24M | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M |
| Accounts Payable | 257.00K | 485.00K | 633.00K | 516.00K | 1.69M | 1.34M |
| Accrued Expenses | 1.30M | 993.00K | 2.47M | 4.25M | 4.94M | 1.21M |
| Current Portion of Leases | 115.00K | 76.00K | 123.00K | 106.00K | ||
| Total Current Liabilities | 1.55M | 1.48M | 3.22M | 4.84M | 6.75M | 2.65M |
| Long-Term Leases | 209.00K | 316.00K | 91.00K | 237.00K | ||
| Total Liabilities | 1.55M | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M |
| Additional Paid-In Capital | 124.24M | 123.95M | 116.16M | 105.67M | 101.26M | 97.64M |
| Retained Earnings | -115.56M | -111.62M | -102.62M | -88.68M | -63.82M | -36.17M |
| Treasury Stock | -1.22M | |||||
| Total Common Equity | 8.69M | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
| Shareholders' Equity | 8.69M | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
| Total Liabilities & Equity | 10.24M | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M |
| Total Debt | 324.00K | 392.00K | 214.00K | 343.00K | ||
| Net Cash (Debt) | 6.69M | 10.37M | 13.94M | 19.39M | 39.68M | 60.82M |
| Net Cash Per Share | 0.89 | 1.63 | 3.11 | 6.60 | 13.95 | 23.45 |
| Filing Date Shares Outstanding | 7.25M | 7.19M | 4.71M | 3.55M | 2.76M | 2.85M |
| Total Common Shares Outstanding | 7.25M | 7.19M | 4.71M | 3.55M | 2.76M | 2.85M |
| Working Capital | 8.40M | 11.95M | 12.82M | 16.06M | 34.99M | 60.04M |
| Book Value Per Share | 1.20 | 1.71 | 2.87 | 4.79 | 13.11 | 21.56 |
| Tangible Book Value | 8.69M | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
| Tangible Book Value Per Share | 1.20 | 1.71 | 2.87 | 4.79 | 13.11 | 21.56 |
| Machinery | 473.00K | 501.00K | 501.00K | 502.00K | 434.00K | |
| Leasehold Improvements | 14.00K | 14.00K | 16.00K | 16.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -7.55M | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M |
| Depreciation & Amortization | 58.00K | 70.00K | 53.00K | 67.00K | 58.00K | 34.00K |
| Stock-Based Compensation | 599.00K | 623.00K | 617.00K | 1.49M | 3.21M | 2.02M |
| Other Operating Activities | 42.00K | 7.00K | ||||
| Change in Accounts Receivable | -1.95M | -1.14M | -487.00K | 903.00K | -64.00K | -2.06M |
| Change in Accounts Payable | -117.00K | -177.00K | 117.00K | -1.17M | 352.00K | 1.18M |
| Change in Other Net Operating Assets | 191.00K | -1.51M | -1.74M | -679.00K | 3.72M | -1.07M |
| Operating Cash Flow | -8.73M | -11.13M | -15.39M | -23.61M | -20.37M | -12.37M |
| Capital Expenditures | -6.00K | -3.00K | -3.00K | -68.00K | -239.00K | |
| Sale of Property, Plant & Equipment | 1.00M | |||||
| Investment in Securities | 3.23M | 5.39M | 2.30M | 15.88M | 19.60M | -45.95M |
| Other Investing Activities | 4.00K | |||||
| Investing Cash Flow | 3.22M | 5.39M | 2.30M | 15.88M | 19.53M | -45.19M |
| Issuance of Common Stock | 5.91M | 7.16M | 9.87M | 3.50M | 410.00K | 58.65M |
| Repurchase of Common Stock | -1.22M | |||||
| Other Financing Activities | 2.43M | |||||
| Financing Cash Flow | 5.91M | 7.16M | 9.87M | 3.50M | -808.00K | 61.07M |
| Net Cash Flow | 403.00K | 1.42M | -3.22M | -4.23M | -1.65M | 3.51M |
| Free Cash Flow | -8.74M | -11.13M | -15.39M | -23.61M | -20.44M | -12.61M |
| Free Cash Flow Per Share | -1.17 | -1.75 | -3.43 | -8.04 | -7.18 | -4.86 |
| Levered Free Cash Flow | -6.19M | -8.20M | -10.86M | -15.49M | -10.87M | -6.07M |
| Unlevered Free Cash Flow | -6.19M | -8.20M | -10.86M | -15.49M | -10.87M | -6.00M |
| Cash Income Tax Paid | -187.00K | -351.00K | ||||
| Change in Working Capital | -1.88M | -2.83M | -2.11M | -948.00K | 4.01M | -1.95M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 8.40M | 10.16M | 34.13M | 6.03M | 36.88M | 78.67M |
| Enterprise Value | 1.72M | 99.94K | 15.09M | -15.23M | -9.34M | 14.76M |
| Last Close Price | 1.16 | 1.65 | 7.24 | 2.04 | 12.80 | 27.60 |
| PB Ratio | 0.97 | 0.82 | 2.52 | 0.35 | 1.02 | 1.28 |
| P/TBV Ratio | 0.97 | 0.82 | 2.52 | 0.35 | 1.02 | 1.28 |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.01 | 0.01 | ||
| Net Debt / Equity Ratio | -0.77 | -0.84 | -1.03 | -1.14 | -1.09 | -0.99 |
| Net Debt / EBITDA Ratio | 0.85 | 1.09 | 0.95 | 0.76 | 1.39 | 4.93 |
| Net Debt / FCF Ratio | 0.77 | 0.93 | 0.91 | 0.82 | 1.94 | 4.82 |
| Quick Ratio | 6.41 | 7.14 | 4.51 | 4.15 | 5.98 | 23.15 |
| Current Ratio | 6.41 | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 |
| Return on Equity (ROE) | -82.17% | -69.54% | -91.34% | -91.02% | -56.60% | -34.53% |
| Return on Assets (ROA) | -46.27% | -38.86% | -47.10% | -48.80% | -33.20% | -20.12% |
| Return on Capital Employed (ROCE) | -91.10% | -77.60% | -107.20% | -147.10% | -78.60% | -20.00% |
| Earnings Yield | -86.81% | -88.57% | -40.86% | -401.76% | -74.96% | -15.86% |
| FCF Yield | -103.94% | -109.62% | -45.08% | -391.69% | -55.42% | -16.03% |
| Buyback Yield / Dilution | -34.42% | -42.10% | -52.79% | -3.26% | -9.70% | -51.71% |